An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

Launched by ELUSYS THERAPEUTICS · Mar 22, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a medication called obiltoxaximab, which is used to treat or prevent inhalational anthrax infections caused by a bacteria known as Bacillus anthracis. The trial aims to understand how well the medication works, its safety, and how it behaves in the body after being given to patients. It will collect information from people who receive this treatment in real-life situations, whether it's during a small anthrax incident or a larger outbreak. The goal is to gather valuable data that can help improve care for patients exposed to anthrax.

Anyone who receives obiltoxaximab for suspected or confirmed anthrax infection may be eligible to participate in this study. This includes men, women (even if pregnant or nursing), and children of all ages. Participants will need to provide consent to join the study, either themselves or through a representative if they cannot. While the study is not yet recruiting, it promises to contribute important insights into the effectiveness and safety of this treatment in managing anthrax infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women (including pregnant and lactating women) and children of all ages who receive obiltoxaximab as part of their clinical care for anthrax infection and are willing and able to give written informed consent themselves or through legally acceptable representative (for minors, unconscious adults or deceased subjects) to participate in the study
• Exclusion Criteria:
• • There are no exclusion criteria defined for this study